Fabrication of Orally Fast Disintegrating Wafer Tablets Containing Cannabis Extract Using Freeze Drying Method

Q1 Medicine Medical Cannabis and Cannabinoids Pub Date : 2024-02-20 DOI:10.1159/000537926
Chaowalit Monton, Poj Kulvanich, Natawat Chankana, Jirapornchai Suksaeree, T. Songsak
{"title":"Fabrication of Orally Fast Disintegrating Wafer Tablets Containing Cannabis Extract Using Freeze Drying Method","authors":"Chaowalit Monton, Poj Kulvanich, Natawat Chankana, Jirapornchai Suksaeree, T. Songsak","doi":"10.1159/000537926","DOIUrl":null,"url":null,"abstract":"Introduction: The development of a novel dosage form for cannabis extract is necessary to improve drug delivery and to also enhance patient convenience.\nMethods: Orally fast disintegrating wafer tablets containing cannabis extract, which were prepared using the freeze drying technique, were developed in this work. The formulation consisted of several key components: cannabis extract as the active compound, Tween® 80 as a surfactant and solubilizer, gelatin and mannitol as structural components, sucralose as a sweetening agent, and sodium methylparaben and sodium propylparaben as preservatives. \nResults: The optimized formulation consists of the following ingredients: 5% cannabis extract, 1.25% Tween® 80, 5% gelatin, 88.34% mannitol, 0.2% sucralose, 0.19% sodium methylparaben, and 0.02% sodium propylparaben. The resulting wafer tablets exhibited the following characteristics: a porous structure, an average weight of approximately 200 mg, minimal weight variation (less than 1.4%), slightly acidic pH (pH 5.12), disintegration within 10 s, low moisture content (less than 3%), a Δ9-tetrahydrocannabinol content of approximately 2.8 mg, and a cannabidiol content of approximately 0.9 mg. Additionally, the wafer tablets rapidly dissolved in simulated saliva fluid containing sodium lauryl sulfate. \nConclusion: This work succeeded in the fabrication of orally disintegrating wafer tablets containing cannabis extract with desired properties.","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"9 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000537926","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The development of a novel dosage form for cannabis extract is necessary to improve drug delivery and to also enhance patient convenience. Methods: Orally fast disintegrating wafer tablets containing cannabis extract, which were prepared using the freeze drying technique, were developed in this work. The formulation consisted of several key components: cannabis extract as the active compound, Tween® 80 as a surfactant and solubilizer, gelatin and mannitol as structural components, sucralose as a sweetening agent, and sodium methylparaben and sodium propylparaben as preservatives. Results: The optimized formulation consists of the following ingredients: 5% cannabis extract, 1.25% Tween® 80, 5% gelatin, 88.34% mannitol, 0.2% sucralose, 0.19% sodium methylparaben, and 0.02% sodium propylparaben. The resulting wafer tablets exhibited the following characteristics: a porous structure, an average weight of approximately 200 mg, minimal weight variation (less than 1.4%), slightly acidic pH (pH 5.12), disintegration within 10 s, low moisture content (less than 3%), a Δ9-tetrahydrocannabinol content of approximately 2.8 mg, and a cannabidiol content of approximately 0.9 mg. Additionally, the wafer tablets rapidly dissolved in simulated saliva fluid containing sodium lauryl sulfate. Conclusion: This work succeeded in the fabrication of orally disintegrating wafer tablets containing cannabis extract with desired properties.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用冷冻干燥法制造含大麻提取物的口服快速崩解片剂
导言:开发新型大麻提取物剂型是必要的:有必要开发一种新型的大麻提取物剂型,以改善给药效果,同时为患者提供更多便利:本研究采用冷冻干燥技术开发了含有大麻提取物的口服快速崩解威化片。配方由几种关键成分组成:大麻提取物作为活性化合物,吐温® 80 作为表面活性剂和增溶剂,明胶和甘露醇作为结构成分,三氯蔗糖作为甜味剂,苯甲酸甲酯钠和苯甲酸丙酯钠作为防腐剂。结果:优化配方由以下成分组成:5% 大麻提取物、1.25% 吐温® 80、5% 明胶、88.34% 甘露醇、0.2% 三氯蔗糖、0.19% 苯甲酸钠和 0.02% 苯丙醇钠。制成的威化片具有以下特征:多孔结构,平均重量约为 200 毫克,重量变化极小(小于 1.4%),pH 值呈弱酸性(pH 值为 5.12),10 秒内崩解,水分含量低(小于 3%),Δ9-四氢大麻酚含量约为 2.8 毫克,大麻二酚含量约为 0.9 毫克。此外,威化片还能在含有十二烷基硫酸钠的模拟唾液中迅速溶解。结论这项工作成功地制造出了含有大麻提取物的口腔崩解威化片,并具有所需的特性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
期刊最新文献
Proceedings of the 2024 Cannabis Clinical Outcomes Research Conference. Development and in vitro Evaluation of Cannabidiol Mucoadhesive Buccal Film Formulations Using Hot-Melt Extrusion Technology. Cannabinoids for the Treatment of Glaucoma: A Review. Long-Term Treatment for Unspecified Anxiety Disorders with Cannabidiol: A Retrospective Case Series from Real-World Evidence in Colombia. Use of Cannabidiol-Dominant Extract as Co-Adjuvant Therapy for Type 2 Diabetes Mellitus Treatment in Feline: Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1